Free Trial
NYSE:PLX

Protalix BioTherapeutics (PLX) Stock Price, News & Analysis

Protalix BioTherapeutics logo
$1.17
0.00 (0.00%)
(As of 10/31/2024 ET)

About Protalix BioTherapeutics Stock (NYSE:PLX)

Key Stats

Today's Range
$1.14
$1.18
50-Day Range
$0.90
$1.18
52-Week Range
$0.82
$1.90
Volume
113,322 shs
Average Volume
329,360 shs
Market Capitalization
$86.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Protalix BioTherapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
37th Percentile Overall Score

PLX MarketRank™: 

Protalix BioTherapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 789th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Protalix BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Protalix BioTherapeutics has received no research coverage in the past 90 days.

  • Read more about Protalix BioTherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Protalix BioTherapeutics are expected to grow by 933.33% in the coming year, from $0.06 to $0.62 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Protalix BioTherapeutics is -5.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Protalix BioTherapeutics is -5.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Protalix BioTherapeutics has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for PLX.
  • Dividend Yield

    Protalix BioTherapeutics does not currently pay a dividend.

  • Dividend Growth

    Protalix BioTherapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for PLX.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Protalix BioTherapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for PLX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Protalix BioTherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.30% of the stock of Protalix BioTherapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 16.53% of the stock of Protalix BioTherapeutics is held by institutions.

  • Read more about Protalix BioTherapeutics' insider trading history.
Receive PLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

PLX Stock News Headlines

Protect Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
See More Headlines

PLX Stock Analysis - Frequently Asked Questions

Protalix BioTherapeutics' stock was trading at $1.78 at the beginning of the year. Since then, PLX stock has decreased by 34.3% and is now trading at $1.17.
View the best growth stocks for 2024 here
.

Protalix BioTherapeutics, Inc. (NYSE:PLX) released its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by $0.05. The business had revenue of $13.47 million for the quarter, compared to analyst estimates of $12.50 million. Protalix BioTherapeutics had a negative trailing twelve-month return on equity of 45.15% and a negative net margin of 38.62%.

Protalix BioTherapeutics's stock reverse split on Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Protalix BioTherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Walmart (WMT) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
8/14/2024
Today
10/31/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Employees
200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+754.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$8.31 million
Pretax Margin
-39.81%

Debt

Sales & Book Value

Annual Sales
$38.05 million
Cash Flow
$0.15 per share
Book Value
$0.47 per share

Miscellaneous

Free Float
68,910,000
Market Cap
$86.05 million
Optionable
Optionable
Beta
0.70
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NYSE:PLX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners